Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
Biomarin Pharmaceutical (NASDAQ:BMRN) has been evaluated by 10 analysts over the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is $108.6, down from $116.17, with a high estimate of $140.00 and a low of $82.00. Analysts from firms including Stifel, RBC Capital, BMO Capital, Piper Sandler, Morgan Stanley, Barclays, Cantor Fitzgerald, Bernstein, and Truist Securities have provided ratings and price target updates, reflecting changes in market conditions and company performance. BioMarin focuses on rare-disease therapies and has seen a revenue growth of 15.04% as of September 30, 2023, but lags behind industry peers. The company has a strong net margin of 6.95%, ROE of 0.83%, ROA of 0.61%, and a low debt-to-equity ratio of 0.22.
December 21, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biomarin Pharmaceutical has received varied analyst ratings with a downward revision in the average price target. The company's strong financial metrics may counterbalance the negative sentiment from the reduced price targets.
While the average price target for Biomarin Pharmaceutical has decreased, indicating a bearish sentiment, the company's strong financial performance, particularly in terms of net margin, ROE, and ROA, could mitigate the negative impact on the stock price in the short term. The mixed analyst ratings suggest uncertainty, leading to a neutral score.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100